Caravel Oculus
AUSTRALIA SUBSIDIARY
Lyman Lee, Ph.D.
Director
Dr. Lyman Lee is dedicated to the development of innovative ophthalmic solutions, driving advancements in the biotech and healthcare industries. With extensive academic and industry experience, he leverages his multidisciplinary expertise in pharmaceutical sciences, business management, and intellectual property strategy to develop high-efficiency, safe, and market-competitive ophthalmic products.
With a forward-looking market perspective and a strong commitment to innovation, Dr. Lee strives to elevate industry standards in eye health, providing superior vision care solutions for consumers worldwide.
Sofie De Meyer, Ph.D.
Director
Dr. Sofie De Meyer is an experienced business leader and Australian resident director with more than 10 years of experience managing complex multidisciplinary projects across the medical and agricultural industries. She holds a Ph.D. in Biochemistry and Biotechnology from Ghent University and is a Graduate of the Australian Institute of Company Directors (GAICD).
With a strong background in corporate governance, business development, research commercialisation, and stakeholder engagement, Dr. De Meyer advises foreign-invested companies on Australian compliance requirements and governance best practices. Her combination of scientific expertise, entrepreneurial experience, and strategic leadership supports Caravel Oculus in strengthening its operations and long-term development in Australia.
Lishan Huang
Director
Ms. Lishan Huang has nearly 15 years of experience in financial accounting and administrative management within the biotechnology and pharmaceutical industries . She has also accumulated extensive practical experience in coordinating across organizations and managing new business initiatives.
Naomi Brook, Ph.D.
R&D Consultant / Clinical Trial Operations
Dr. Naomi Brook is a clinical research and development professional with 15 years of experience across sponsor, contract research organisation (CRO), and clinical trial site environments. She has led and supported Phase I–III clinical trials in therapeutic areas including oncology, chronic pain, mental health, and metabolic disease.
Dr. Brook holds a Ph.D. in Pharmacy, a Master of Biomedical Science, and a Bachelor of Biomedical Science. Her expertise includes clinical trial strategy and design, project and operational management, GCP and regulatory compliance, cross-functional team leadership, and risk management. As an R&D Consultant, she provides independent clinical operations and technical oversight to support Caravel Oculus’s research and clinical development activities in Australia.